Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
4.780
+0.230 (5.05%)
Oct 15, 2026, 4:00 PM EDT - Market closed
Entrada Therapeutics Revenue
Entrada Therapeutics had revenue of $898.00K in the quarter ending June 30, 2026, a decrease of -53.95%. This brings the company's revenue in the last twelve months to $4.69M, down -94.10% year-over-year. In the year 2025, Entrada Therapeutics had annual revenue of $25.42M, down -87.94%. That makes Entrada Therapeutics the 40,132nd largest company in the world by revenue and 5,339th in the United States.
Revenue (ttm)
$4.69M
Revenue Growth
-94.10%
P/S Ratio
36.78
Revenue / Employee
$30,829
Employees
152
Market Cap
172.35M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 25.42M | -185.36M | -87.94% |
| Dec 31, 2024 | 210.78M | 81.77M | 63.38% |
| Dec 31, 2023 | 129.01M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 50.94M |
| Sutro Biopharma | 45.70M |
| Precision BioSciences | 45.06M |
| MediWound | 11.86M |
| Adagene | 9.29M |
| Whitehawk Therapeutics | 7.15M |
| Oramed Pharmaceuticals | 2.00M |
| Compass Therapeutics | 850.00K |
TRDA News
- 1 day ago - Entrada Therapeutics reports data from Cohort 1 of ELEVATE-45-201 clinical study - TheFly
- 1 day ago - Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study - GlobeNewsWire
- 1 day ago - Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 - GlobeNewsWire
- 5 weeks ago - Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program - GlobeNewsWire
- 5 weeks ago - Entrada Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 6 weeks ago - Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Entrada Therapeutics price target raised to $11 from $10 at Roth Capital - TheFly
- 2 months ago - Entrada Therapeutics reports Q2 EPS ($1.01), consensus ($1.04) - TheFly